Selective overexpression of ACE in the heart also results in morphological changes in the atria, arrhythmia, and sudden death (31) . The ACE substrate angiotensin I in such models most probably comes from the plasma, although there is evidence indicating that angiotensinogen, renin, and ACE exist in the heart, implying that some tissues may possess the enzymatic machinery required to generate angiotensin II locally (1, 23) . Antisense oligonucleotides against ACE, on the other hand, are reported to prevent neointimal formation after balloon angioplasty (22) , and ACE inhibitors decrease vascular hypertrophy in hypertensive animals (4).
The evidence for an ACE signaling pathway
ACE inhibitors, such as ramiprilat, exert beneficial effects on endothelial function and vascular remodeling (19, 25) as well as protect against the progression of atherosclerosis and the occurrence of cardiovascular events in humans (11) (FIG- URE 1) . Although the beneficial effects of ACE inhibitors are generally attributed to a decrease in the ACEmediated generation of angiotensin II and the accumulation of bradykinin (30) , a number of the effects of this class of compounds cannot be accounted for by inhibition of the enzyme per se. For example, a cross-talk has been proposed to exist between ACE and the bradykinin B 2 receptor (2, 20) phorylation of ACE by CK2 stabilizes its localization in the plasma membrane, and either the mutation of this site or the inhibition of CK2 both enhance the cleavage/secretion of the enzyme (14) . CK2 is not the only protein that associates with the cytoplasmic tail of ACE in endothelial cells. Using ACE immunoprecipitated from ACE-overexpressing cells as well as an affinity column composed of a peptide corresponding to the cytoplasmic tail of ACE, mitogen-activated protein kinase kinase 7 and the c-Jun NH 2 -terminal kinase (JNK) were also found to associate with the intracellular domain of the enzyme (FIGURE 3). Moreover, the binding of an ACE inhibitor (ramiprilat or perindoprilat) to ACE enhances the CK2-dependent phosphorylation of Ser 1270 as well as the activity of ACE-associated JNK. Although the binding of the ACE substrate angiotensin I does not increase the activity of ACE-associated JNK, the binding of bradykinin does increase kinase activity, albeit to a lesser extent than an ACE inhibitor.
tion of extracellular signal-regulated kinases 1/2) in cells desensitized to bradykinin by prior stimulation with high concentrations of the agonist (2).
For a cross-talk to exist between ACE and the B 2 receptor, or other signaling cascades, it was reasoned that the binding of an ACE inhibitor to ACE should be able to elicit an intracellular event and that ACE should be capable of outside-in signaling. Moreover, the cytoplasmic tail of ACE should be able to bind soluble intracellular signal molecules and/or adaptor proteins, which initiate a chain of events ultimately linking to effects such as the reactivation of the B 2 kinin receptor. In all of the species studied to date, the short cytoplasmic tail of ACE contains between three and five serine residues (FIGURE 2), one of which (Ser 1270 of the human sequence) is located in a highly conserved 13-amino-acid sequence at the extreme COOH-terminal end of the protein.
The serine residue in question is phosphorylated by the casein kinase 2 (CK2), which also physically interacts with the protein (14) . The basal phos-
The increase in JNK activity results in the translocation of phosphorylated cJun to the nucleus, an enhanced binding of the activator protein-1 transcription factor to DNA, followed by the increased expression of ACE (15) and cyclooxygenase-2 (COX-2) (16). Although at first glance it seems unlikely that an ACE-inhibitor-induced increase in the expression of ACE or COX-2 could be associated with improved endothelial cell function, increased ACE levels have been demonstrated in lung tissue and plasma from ACE-inhibitor-treated rats (5) and in the serum from patients who distinctly benefit from ACE inhibitor therapy (3). Thus it could be expected that an increase in ACE expression and the corresponding increased angiotensin II-generating capacity would be expected to aggravate the atherosclerotic process. However, in the continued presence of an ACE inhibitor, the increase in ACE expression would also increase "ACE signaling," which could contribute to the overall long-term positive effects. The ACE inhibitor-induced increase in COX-2 expression is also beneficial, because the main product of this enzyme in endothelial cells is the vasodilator and anti-aggregatory eicosanoid prostacyclin. Indeed, prostacyclin production is significantly increased in subjects treated with ACE inhibitors (17) , and selective COX-2 inhibition diminishes the positive effects of ACE inhibitors on blood pressure (13, 26) . Although experimental data suggesting an intracellular cross-talk between ACE and the B 2 receptor initiated the investigation of "ACE signaling," the signal cascade described to date appears to be independent of the presence of B 2 receptors.
ACE2
A zinc metalloprotease that shares 42% identity with the catalytic site of somatic ACE is highly expressed in vascular endothelial cells of the heart, kidney, and testis and can be shed from cells by cleavage NH 2 -terminal to the transmembrane domain (8, 28 Potentially phosphorylatable serine/tyrosine residues as well as predicted kinases are marked. The last 13 amino acids are highlighted to indicate the high degree of conservation (100%), and the total number of amino acids of each ACE enzyme is marked at right.
ACE2 hydrolyzes a spectrum of peptides, in particular angiotensin II to angiotensin-(1-7) and angiotensin I to angiotensin-(1-9) (FIGURE 4), but the catalytic efficiency of ACE2 is 400-fold higher with angiotensin II as a substrate than with angiotensin I (k cat /K m = 1.8 × 10 6 vs. 4.9 × 10 3 M -1 иs -1 ) (29) . The enzyme can also cleave des-Arg 9 -bradykinin but does not hydrolyze bradykinin and is insensitive to ACE inhibitors (8, 28, 29) . The fact that ACE2 metabolizes angiotensin II to give the vasodilator angiotensin-(1-7) has been interpreted to mean that ACE2 provides a counterbalance, preventing the deleterious consequences of the overactivity of the classical renin-angiotensin system (7). Indeed, the improvement in ventricular contractility observed after coronary artery ligation in rats treated with an angiotensin II type-1 receptor blocker was associated with a significant increase in ACE 2 mRNA expression (12) . Modifying the expression of ACE2 has marked consequences on the heart, findings that fit well with the report that an ACE2 homolog (ACER) in Drosophila is required for normal heart development (6). However, the exact relationship between ACE2 levels and cardiac function remains to be clarified, because the cardiac-specific overexpression of ACE2 was associated with severe, progressive conduction and rhythm disturbances, ventricular tachycardia, and sudden death (9), whereas aging ACE2 knockout mice develop a significant defect in both the speed and the overall percentage of contraction (6). ACE2 levels are also altered in diabetes, but again the situation is rather confusing and the expression of ACE2 seems to alter during the progression of the disease. For example, ACE2 expression is reported to be increased in young mice with type 2 diabetes and was thought to be renoprotective (33) , whereas in a rat model of streptozocin-induced diabetes the tubule ACE2 protein levels were reduced compared with the control group, an effect that was prevented by treatment with an ACE inhibitor (27) .
Summary
It seems that just when we thought that we knew all there was to know about the renin-angiotensin system, we find that we don't even know half the story. The majority of the beneficial effects of ACE inhibitors have been attributed to the inhibition of angiotensin II production, but it is probable that the ACE-inhibitorinduced signaling process recently described contributes to the clinical outcome. Currently the best "agonists" of the ACE signaling cascade seem to be ACE inhibitors rather than known ACE substrates, and it will be interesting to determine whether a better endogenous agonist for this signaling pathway exists and whether changes in agonist concentration correlate with the extent of cardiovascular disease. ACE2 remains a relatively unknown but potentially cardioprotective enzyme, and although current research has concentrated on assess- 
